MYC and neoplasm: Several compoundsthat directly or indirectly inhibit MYC have exhibited anticanceractivity in preclinical tumor models, but to this point, researchefforts have failed to bring a suitable MYC inhibitor to the clinic.7−9 MYC is considered a difficult target (often the term “undruggable”is used for this protein) since it is a disordered protein.